FDA Panelist Questions Marketing Benefits From Soliris REMS
Executive Summary
Cleveland Clinic hematologist suggests eculizumab risk management plan provides Alexion with an opportunity for direct-to-consumer marketing.
You may also be interested in...
When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?
Waking Up to REMS (Part 3): Redefining Marketing
FDA's new post-marketing safety authorities place unprecedented burdens on pharmaceutical marketers. But they do something else: redefine a favorite target of industry critics as a regulatory requirement rather than a suspicious activity.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.